Spain’s first pilot integrating economic evaluations into drug reimbursement decisions reveals progress, challenges, and lessons for the future.
This study by Laura Vallejo-Torres, Juan Oliva-Moreno, and Félix Lobo examines how economic evaluations (EEs) were incorporated into Spain’s therapeutic positioning reports (IPTs) from 2021–2023. It analyses uptake, methods, and quality to assess the country’s progress in aligning pricing and reimbursement decisions with efficiency principles.
Despite political momentum, the results show limited adoption and wide methodological variation. The findings underscore the need for clearer regulation, stronger institutional capacity, and better coordination to embed economic evaluation as a core component of Spain’s healthcare decision-making.
